12,000
Participants
Start Date
February 20, 2025
Primary Completion Date
August 15, 2029
Study Completion Date
August 15, 2029
Intensive LDL-C control
"By Statin, Ezetimibe, or PCSK9i, prescribed according to LDL-C level at baseline and follow-up;~For patients with baseline LDL-C level \< 3.0 mmol/L, it is recommended to start lipid control by statin + PCSK9i; for LDL-C level ≥ 3.0 mmol/L, statin + ezetimibe + PCSK9i"
Conventional LDL-C control
"By Statin, Ezetimibe, or PCSK9i, prescribed according to LDL-C level at baseline and follow-up;~For patients with baseline LDL-C level \< 3.0 mmol/L, it is recommended to start lipid control by statin alone or statin + ezetimibe; for LDL-C level ≥ 3.0 mmol/L, statin + PCSK9i"
Xijing Hospital, Xi'an
Xijing Hospital
OTHER